Vonoprazan, sold under the brand name Voquezna among others, is a first-in-class potassium-competitive acid blocker medication.[2] Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.[2] It is a potassium-competitive acid blocker.[1]
Clinical data | |
---|---|
Trade names | Voquezna, Takecab, Vocinti |
AHFS/Drugs.com | Voquezna |
License data |
|
Routes of administration | By mouth |
Drug class | Potassium-competitive acid blocker |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Unknown |
Protein binding | 80% |
Metabolism | Liver, by cytochrome P450 (3A4, 2B6, 2C19, 2D6) |
Elimination half-life | 7.7 h |
Duration of action | > 24 h |
Excretion | Kidney |
Identifiers | |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
ChEMBL |
|
PDB ligand |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C17H16FN3O2S |
Molar mass | 345.39 g·mol−1 |
3D model (JSmol) |
|
| |
|
It was approved in Japan in February 2015,[3][4] and in Russia in April 2021.[5] Vonoprazan was approved for medical use in the United States in November 2023.[1][6] Co-packaged combinations of vonoprazan with amoxicillin and vonoprazan with amoxicillin and clarithromycin are available.[7][8]
Vonoprazan is indicated for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults; to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults; in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection in adults; in combination with amoxicillin for the treatment of H. pylori infection in adults.[1][7][9]
Vonoprazan is the international nonproprietary name (INN).[10]